AR068536A1 - INACTIVATED ANTIGRIPAL VACCINE - Google Patents

INACTIVATED ANTIGRIPAL VACCINE

Info

Publication number
AR068536A1
AR068536A1 ARP080104130A ARP080104130A AR068536A1 AR 068536 A1 AR068536 A1 AR 068536A1 AR P080104130 A ARP080104130 A AR P080104130A AR P080104130 A ARP080104130 A AR P080104130A AR 068536 A1 AR068536 A1 AR 068536A1
Authority
AR
Argentina
Prior art keywords
inactivated
vaccine
influenza
virus
influenza virus
Prior art date
Application number
ARP080104130A
Other languages
Spanish (es)
Inventor
Henrikus Lodewijk Glansbeek
Jacobus Gerardus Maria Heldens
Original Assignee
Nobilon Internat B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobilon Internat B V filed Critical Nobilon Internat B V
Publication of AR068536A1 publication Critical patent/AR068536A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a vacunas antigripales inactivadas y con adyuvantes. La presente brinda una vacuna que supera muchas de las desventajas de las vacunas antigripales inactivadas existentes. La presente brinda una vacuna antigripal inactivada, que comprende el virus de la influenza entero inactivado con beta propiolactona (BPL) y que comprende, como adyuvante, uno o más derivados de monosacáridos o disacáridos que tienen al menos uno pero no más de N-1 grupos éster de ácido graso y, opcionalmente, uno pero no más de N-1 grupos éster de sulfato, donde N es el numero de grupos hidroxilo del monosacárido o disacárido del cual se obtiene el derivado. El virus de la influenza en una vacuna de acuerdo con la presente se obtiene, preferentemente, de un cultivo celular. Los métodos para producir el virus de la influenza en un cultivo celular son conocidos en el arte. El virus se puede cultivar en células de origen mamífero, aviar; o humano, tales como células Madin Darby Canine Kidney (MDCK), Vero, MDBK, CLDK, EBx o PerC6.This refers to inactivated influenza vaccines and adjuvants. This provides a vaccine that overcomes many of the disadvantages of existing inactivated influenza vaccines. This provides an inactivated influenza vaccine, comprising the whole influenza virus inactivated with beta propiolactone (BPL) and comprising, as an adjuvant, one or more monosaccharide or disaccharide derivatives having at least one but not more than N-1 fatty acid ester groups and, optionally, one but not more than N-1 sulfate ester groups, where N is the number of hydroxyl groups of the monosaccharide or disaccharide from which the derivative is obtained. The influenza virus in a vaccine according to the present is preferably obtained from a cell culture. The methods for producing influenza virus in a cell culture are known in the art. The virus can be grown in cells of mammalian, avian origin; or human, such as Madin Darby Canine Kidney (MDCK), Vero, MDBK, CLDK, EBx or PerC6 cells.

ARP080104130A 2007-09-24 2008-09-24 INACTIVATED ANTIGRIPAL VACCINE AR068536A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97456807P 2007-09-24 2007-09-24
EP07117050 2007-09-24

Publications (1)

Publication Number Publication Date
AR068536A1 true AR068536A1 (en) 2009-11-18

Family

ID=39590199

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104130A AR068536A1 (en) 2007-09-24 2008-09-24 INACTIVATED ANTIGRIPAL VACCINE

Country Status (6)

Country Link
EP (1) EP2195020A1 (en)
CN (1) CN101808659A (en)
AR (1) AR068536A1 (en)
BR (1) BRPI0817230A2 (en)
TW (1) TW200927928A (en)
WO (1) WO2009040343A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278999B2 (en) 2012-01-27 2016-03-08 Newport Laboratories Influenza C virus and vaccine
US10647737B2 (en) 2014-07-11 2020-05-12 National Research Council Of Canada Sulfated-glycolipids as adjuvants for vaccines
CN104792985A (en) * 2015-04-21 2015-07-22 乾元浩生物股份有限公司 Method for qualitatively and quantitatively analyzing effective components of avian influenza virus antigen for poultry
CA3083576A1 (en) * 2017-09-07 2019-03-14 Hawaii Biotech, Inc. Filovirus vaccine and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104767A1 (en) * 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US20090304742A1 (en) * 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant

Also Published As

Publication number Publication date
EP2195020A1 (en) 2010-06-16
BRPI0817230A2 (en) 2017-06-06
WO2009040343A1 (en) 2009-04-02
CN101808659A (en) 2010-08-18
TW200927928A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
BR112013022397A2 (en) vaccines combined with lower doses of antigen and / or adjuvant
BR112018012873A2 (en) zika virus vaccine
CO2017011245A2 (en) Group B streptococcus protein-polysaccharide conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates and their uses
BR112018008102A2 (en) respiratory syncytial virus vaccine
CL2016003048A1 (en) Panonin analogues minimizes synthesis and use thereof.
BR112018008090A2 (en) herpes simplex virus vaccine.
BR112013029834A2 (en) individualized cancer vaccines
BR112012004698A2 (en) methods for reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with improved immunonugenicity.
TR201908003T4 (en) Advanced adjuvant formulations containing TLR4 agonists and their method of use.
BR112012020839A2 (en) vaccines for use in the prophylaxis and treatment of influenza virus disease
BRPI0918806A2 (en) composition comprising chitosan for ocular administration of vanines in birds
AR073959A1 (en) COMBINATION VACCINE WITH TOS FERINA ACELULAR AND METHOD FOR THEIR ELABORATION
BR112015018270A2 (en) compositions comprising 15-ohepa and methods of using them
BR112018010503A2 (en) bird egg, method for replicating a virus, virus, method for producing a vaccine composition, vaccine composition, transgenic bird, and method for producing a bird
UY33297A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT UNDERSTANDS AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME
AR068536A1 (en) INACTIVATED ANTIGRIPAL VACCINE
PE20151588A1 (en) VACCINE AGAINST DENGUE VIRUS
BR112015005056A2 (en) combination vaccines with meningococcus serogroup b and d / t / p
AR068419A1 (en) LIVES OF MYCOPLASMA ATENUATED LIVE
BR112015000585A8 (en) method for preparing a mutant strain of mycoplasma hyopneumoniae, vectors, mutant strain, vaccine, vaccination kit, and uses of the vector and mutant strain
BR112019009131A2 (en) swine parvovirus vaccine, swine respiratory and reproductive syndrome virus, and swine production methods
BR112012030659B8 (en) ATTENUATED LIVE PARVOVIRUS, VACCINES THAT UNDERSTAND AND METHOD FOR MANUFACTURING SUCH VACCINES
CO2017007057A2 (en) Foot and mouth disease vaccine
CU24579B1 (en) PREPARATION PROCESS OF AN ATTENUATED TETRAVALENT VACCINE AGAINST DENGUE VIRUS
BR112017004746A2 (en) methods for preparing adjuvanted virosomes, for optimizing the adjuvant / antigen ratio of a virosome-based vaccine and for immunizing an individual against a disease, adjuvanted virosome, pharmaceutical composition, and immunogenic composition.

Legal Events

Date Code Title Description
FB Suspension of granting procedure